Your browser doesn't support javascript.
loading
Prevalence of Plasmodium falciparum and Non-falciparum Infections by Photo-Induced Electron Transfer-PCR in a Longitudinal Cohort of Individuals Enrolled in a Mass Drug Administration Trial in Southern Province, Zambia.
Chishimba, Sandra; Mwenda, Mulenga; Mambwe, Brenda; Mulube, Conceptor; Chalwe, Victor; Moonga, Hawela; Hamainza, Busiku; Chizema-Kawesha, Elizabeth; Steketee, Richard W; Domingo, Gonzalo; Fraser, Maya; Kahn, Maria; Pal, Sampa; Silumbe, Kafula; Conner, Ruben O; Bennett, Adam; Porter, Travis R; Eisele, Thomas P; Miller, John M; Bridges, Daniel J.
Affiliation
  • Chishimba S; 1PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.
  • Mwenda M; 1PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.
  • Mambwe B; 1PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.
  • Mulube C; 1PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.
  • Chalwe V; 2Zambia Ministry of Health Provincial Medical Office, Mansa, Zambia.
  • Moonga H; 3National Malaria Elimination Centre, Zambia Ministry of Health, Lusaka, Zambia.
  • Hamainza B; 3National Malaria Elimination Centre, Zambia Ministry of Health, Lusaka, Zambia.
  • Chizema-Kawesha E; 3National Malaria Elimination Centre, Zambia Ministry of Health, Lusaka, Zambia.
  • Steketee RW; 4PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Seattle, Washington.
  • Domingo G; 4PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Seattle, Washington.
  • Fraser M; 4PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Seattle, Washington.
  • Kahn M; 4PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Seattle, Washington.
  • Pal S; 4PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Seattle, Washington.
  • Silumbe K; 1PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.
  • Conner RO; 4PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Seattle, Washington.
  • Bennett A; 5Malaria Elimination Initiative, Global Health Group, University of California San Francisco, San Francisco, California.
  • Porter TR; 6Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.
  • Eisele TP; 6Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.
  • Miller JM; 1PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.
  • Bridges DJ; 1PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.
Am J Trop Med Hyg ; 103(2_Suppl): 82-89, 2020 08.
Article in En | MEDLINE | ID: mdl-32618252
ABSTRACT
Malaria burden in Zambia has significantly declined over the last decade because of improved coverage of several key malaria interventions (e.g., vector control, case management, bed net distributions, and enhanced surveillance/responses). Campaign-based mass drug administration (MDA) and focal MDA (fMDA) were assessed in a trial in Southern Province, Zambia, to identify its utility in elimination efforts. As part of the study, a longitudinal cohort was visited and tested (by PCR targeting the 18s rRNA and a Plasmodium falciparum-specific rapid diagnostic test [RDT] from SD Bioline) every month for the trial duration (18 months). Overall, there was high concordance (> 97%) between the PCR and RDT results, using the PCR as the gold standard. The RDTs had high specificity and negative predictive values (98.5% and 98.6%, respectively) but low sensitivity (53.0%) and a low positive predictive value (53.8%). There was evidence for persistent antigenemia affecting the low specificity of the RDT, while false-negative RDTs were associated with a lower parasite density than true positive RDTs. Plasmodium falciparum was the dominant species identified, with 98.3% of all positive samples containing P. falciparum. Of these, 97.5% were mono-infections and 0.8% coinfections with one other species. Plasmodium malariae was found in 1.4% of all positive samples (50% mono-infections and 50% coinfections with P. falciparum), whereas Plasmodium ovale was found in 1.1% of all positive samples (90% mono-infections and 10% coinfections with P. falciparum). Although MDA/fMDA appeared to reduce P. malariae prevalence, P. ovale prevalence appeared unchanged.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Plasmodium falciparum / Malaria, Falciparum / Real-Time Polymerase Chain Reaction / Mass Drug Administration / Malaria / Antimalarials Type of study: Clinical_trials / Diagnostic_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Country/Region as subject: Africa Language: En Journal: Am J Trop Med Hyg Year: 2020 Document type: Article Affiliation country: Zambia

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Plasmodium falciparum / Malaria, Falciparum / Real-Time Polymerase Chain Reaction / Mass Drug Administration / Malaria / Antimalarials Type of study: Clinical_trials / Diagnostic_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Country/Region as subject: Africa Language: En Journal: Am J Trop Med Hyg Year: 2020 Document type: Article Affiliation country: Zambia